Immunotherapy for Prostate Cancer: An Emerging Treatment Modality

Charles G. Drake

Research output: Contribution to journalArticle

Abstract

This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)121-129
Number of pages9
JournalUrologic Clinics of North America
Volume37
Issue number1
DOIs
StatePublished - Feb 2010

Fingerprint

Active Immunotherapy
Immunotherapy
Prostatic Neoplasms
Monoclonal Antibodies
Therapeutics

Keywords

  • CTLA4
  • Lymphocyte
  • PD-1
  • Prostate cancer
  • T cell
  • Vaccine

ASJC Scopus subject areas

  • Urology

Cite this

Immunotherapy for Prostate Cancer : An Emerging Treatment Modality. / Drake, Charles G.

In: Urologic Clinics of North America, Vol. 37, No. 1, 02.2010, p. 121-129.

Research output: Contribution to journalArticle

@article{52ff1fed1792458f9f354a646ed48609,
title = "Immunotherapy for Prostate Cancer: An Emerging Treatment Modality",
abstract = "This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.",
keywords = "CTLA4, Lymphocyte, PD-1, Prostate cancer, T cell, Vaccine",
author = "Drake, {Charles G.}",
year = "2010",
month = "2",
doi = "10.1016/j.ucl.2009.11.001",
language = "English (US)",
volume = "37",
pages = "121--129",
journal = "Urologic Clinics of North America",
issn = "0094-0143",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Immunotherapy for Prostate Cancer

T2 - An Emerging Treatment Modality

AU - Drake, Charles G.

PY - 2010/2

Y1 - 2010/2

N2 - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

AB - This article examines prostate cancer as a target for immunotherapy and investigates active immunotherapy for prostate cancer, combining conventional therapy with active immunotherapy, immune modulators (brakes and accelerators), and monoclonal antibodies.

KW - CTLA4

KW - Lymphocyte

KW - PD-1

KW - Prostate cancer

KW - T cell

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=75349096325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75349096325&partnerID=8YFLogxK

U2 - 10.1016/j.ucl.2009.11.001

DO - 10.1016/j.ucl.2009.11.001

M3 - Article

C2 - 20152525

AN - SCOPUS:75349096325

VL - 37

SP - 121

EP - 129

JO - Urologic Clinics of North America

JF - Urologic Clinics of North America

SN - 0094-0143

IS - 1

ER -